Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 2/20 | 0.53 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
| ▸ | FURIN | P09958 | 7/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | CPA1 | P15085 | 1/20 | 0.47 |
| ▸ | CPA2 | P48052 | 1/20 | 0.47 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10609149 | 0.93 | SIRT6 (0.53) | GNPATSIRT6SIRT1FURINFOLH1 | |
| SCHEMBL30598012 | 0.93 | SIRT6 (0.53) | GNPATSIRT6SIRT1FURINFOLH1 | |
| SCHEMBL29396098 | 0.93 | GNPAT (0.60) | GNPATSIRT6SIRT1FOLH1CPA1 | |
| SCHEMBL29396725 | 0.93 | GNPAT (0.60) | GNPATSIRT6SIRT1FOLH1CPA1 | |
| SCHEMBL29394494 | 0.93 | GNPAT (0.60) | GNPATSIRT6SIRT1FOLH1CPA1 | |
| SCHEMBL31655526 | 0.92 | KDM4E (0.50) | GNPATSIRT6SIRT1FURINFOLH1 | |
| SCHEMBL29396101 | 0.91 | SIRT6 (0.55) | GNPATSIRT6SIRT1FURINFOLH1 | |
| SCHEMBL14669549 | 0.90 | GNPAT (0.45) | GNPATSIRT6SIRT1FURINFOLH1 | |
| SCHEMBL14669746 | 0.90 | GNPAT (0.45) | GNPATSIRT6SIRT1FURINFOLH1 | |
| SCHEMBL29394605 | 0.90 | SIRT6 (0.56) | GNPATSIRT6SIRT1FURINFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4482853-A1 | ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES | RESOTHER PHARMA A/S (DK) | 2025-01-01 | — | — | EP | claimed |
| CN-118891273-A | Annexin A1 derived polypeptide analogs | 雷索特制药股份有限公司 | 2024-11-01 | — | — | CN | claimed |
| US-20230303640-A1 | EXENDIN-4 PEPTIDE ANALOGS | TXP PHARMA AG (CH) | 2023-09-28 | — | — | US | claimed |
| US-20230295255-A1 | ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES | RESOTHER PHARMA APS (DK) | 2023-09-21 | — | — | US | claimed |
| WO-2023161323-A1 | ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES | RESOTHER PHARMA A/S (DK) | 2023-08-31 | — | — | WO | claimed |
| CN-116390938-A | Exendin-4 analogues | TXP制药股份有限公司 | 2023-07-04 | — | — | CN | claimed |
| EP-4200320-A1 | ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES | RESOTHER PHARMA A/S (DK) | 2023-06-28 | — | — | EP | claimed |
| EP-4196495-A1 | EXENDIN-4 PEPTIDE ANALOGUES | TXP Pharma GmbH (CH) | 2023-06-21 | — | — | EP | claimed |
| US-20220133839-A1 | PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S) | TXP PHARMA GMBH (CH) | 2022-05-05 | — | — | US | claimed |
| WO-2022034062-A1 | EXENDIN-4 PEPTIDE ANALOGUES | TXP PHARMA AG (CH) | 2022-02-17 | — | — | WO | claimed |
| US-20250388632-A1 | ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES | RESOTHER PHARMA AS (DK) | 2025-12-25 | — | — | US | disclosed |
| EP-4482853-A1 | ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES | RESOTHER PHARMA A/S (DK) | 2025-01-01 | — | — | EP | disclosed |
| CN-118891273-A | Annexin A1 derived polypeptide analogs | 雷索特制药股份有限公司 | 2024-11-01 | — | — | CN | disclosed |
| US-20230303640-A1 | EXENDIN-4 PEPTIDE ANALOGS | TXP PHARMA AG (CH) | 2023-09-28 | — | — | US | disclosed |
| WO-2023161323-A1 | ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES | RESOTHER PHARMA A/S (DK) | 2023-08-31 | — | — | WO | disclosed |
| CN-116390938-A | Exendin-4 analogues | TXP制药股份有限公司 | 2023-07-04 | — | — | CN | disclosed |
| EP-4200320-A1 | ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES | RESOTHER PHARMA A/S (DK) | 2023-06-28 | — | — | EP | disclosed |
| EP-4196495-A1 | EXENDIN-4 PEPTIDE ANALOGUES | TXP Pharma GmbH (CH) | 2023-06-21 | — | — | EP | disclosed |
| US-20220133839-A1 | PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S) | TXP PHARMA GMBH (CH) | 2022-05-05 | — | — | US | disclosed |
| WO-2022034062-A1 | EXENDIN-4 PEPTIDE ANALOGUES | TXP PHARMA AG (CH) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388632-A1 | ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES | ANXA11, ANXA1, ANXA4 | GNPAT 4073/4885SIRT6 4647/4885SIRT1 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.